Platelet glycoprotein IIb/IIIa inhibitors - Basic and clinical aspects

被引：51

作者：

Nurden, AT ^{[1
]}

Poujol, C

Durrieu-Jais, C

Nurden, P

机构：

[1] Hop Cardiol, CNRS, UMR 5533, F-33604 Pessac, France

[2] Hop Cardiol, Inst Federatif Rech Coeur Vaisseaux Thrombose, Unite Soins Intensifs, F-33604 Pessac, France

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 1999年 / 19卷 / 12期

关键词：

glycoproteins; abciximab; platelet aggregation; antithrombotic drugs;

D O I：

10.1161/01.ATV.19.12.2835

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2835 / 2840

页数：6

共 41 条

[11]

Hanrath P, 1997, CIRCULATION, V96, P1445

[12] Inhibition of platelet-mediated clot retraction by integrin antagonists [J].

Hantgan, RR ;

Mousa, SA .

THROMBOSIS RESEARCH, 1998, 89 (06) :271-279

[13] Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban - Results of a multicenter, placebo-controlled, randomized trial [J].

Kereiakes, DJ ;

Kleiman, NS ;

Ferguson, JJ ;

Masud, Z ;

Broderick, TM ;

Abbottsmith, CW ;

Runyon, JP ;

Anderson, LC ;

Anders, RJ ;

Dreiling, RJ ;

Hantsbarger, GL ;

Bryzinski, B ;

Topol, EJ .

CIRCULATION, 1998, 98 (13) :1268-1278

[14] DIFFERENTIAL INHIBITION OF PLATELET-AGGREGATION INDUCED BY ADENOSINE-DIPHOSPHATE OR A THROMBIN RECEPTOR-ACTIVATING PEPTIDE IN PATIENTS TREATED WITH BOLUS CHIMERIC 7E3 FAB - IMPLICATIONS FOR INHIBITION OF THE INTERNAL POOL OF GPIIB/IIIA RECEPTORS [J].

KLEIMAN, NS ;

RAIZNER, AE ;

JORDAN, R ;

WANG, AL ;

NORTON, D ;

MACE, KF ;

JOSHI, A ;

COLLER, BS ;

WEISMAN, HF .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (07) :1665-1671

[15] Increased platelet responsiveness following coronary stenting - Heparin as a possible aetiological factor in stent thrombosis [J].

Knight, CJ ;

Panesar, M ;

Wilson, DJ ;

Patrineli, A ;

Chronos, N ;

Wright, C ;

Clarke, D ;

Patel, D ;

Fox, K ;

Goodall, AH .

EUROPEAN HEART JOURNAL, 1998, 19 (08) :1239-1248

[16] Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade [J].

Mascelli, MA ;

Lance, ET ;

Damaraju, L ;

Wagner, CL ;

Weisman, HF ;

Jordan, RE .

CIRCULATION, 1998, 97 (17) :1680-1688

[17] Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802 [J].

Mousa, SA ;

Olson, RE ;

Bozarth, JM ;

Lorelli, W ;

Forsythe, MS ;

Racanelli, A ;

Gibbs, S ;

Schlingman, K ;

Bozarth, T ;

Kapil, R ;

Wityak, J ;

Sielecki, TM ;

Wexler, RR ;

Thoolen, MJ ;

Slee, A ;

Reilly, TM ;

Anderson, PS ;

Friedman, PA .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (02) :169-176

[18] ''Rescue'' utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty [J].

Muhlestein, JB ;

Karagounis, LA ;

Treehan, S ;

Anderson, JL .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (07) :1729-1734

[19] Distribution of ligand-occupied alpha(IIb)beta(3) in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6 [J].

Nurden, P ;

Humbert, M ;

Piotrowicz, RS ;

Bihour, C ;

Poujol, C ;

Nurden, AT ;

Kunicki, TJ .

BLOOD, 1996, 88 (03) :887-899

[20]

Nurden P, 1997, THROMB HAEMOSTASIS, V78, P1305

← 1 2 3 4 5 →